Episodic kinesigenic dyskinesia 2

Summary

Episodic kinesigenic dyskinesia 2 (MONDO:0012603) is a disease. A subtype of episodic kinesigenic dyskinesia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	episodic kinesigenic dyskinesia 2
Mondo ID	MONDO:0012603
MeSH	C567026
OMIM	611031
DOID	DOID:0090054
UMLS	C1970238
MedGen	410022
GARD	0015506
Is cancer (heuristic)	no

Also known as: EKD2 · episodic kinesigenic dyskinesia 2 · episodic kinesigenic dyskinesia type 2

Disease family

This is a subtype of episodic kinesigenic dyskinesia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by body system or component › nervous system disorder › movement disorder › extrapyramidal and movement disease › dystonic disorder › inherited dystonia › combined dystonia › paroxysmal dystonia › paroxysmal dyskinesia › episodic kinesigenic dyskinesia › episodic kinesigenic dyskinesia 2

Related subtypes (2): episodic kinesigenic dyskinesia 1, episodic kinesigenic dyskinesia 3

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.